Abstract | OBJECTIVE: METHOD: For this 14-week, double-blind, flexible-dose (25-600 mg/day) topiramate trial, 61 outpatients (53 women, eight men) with binge eating disorder who were obese (body mass index >/=30 kg/m(2)) were randomly assigned to receive topiramate ( N=30) or placebo (N=31). The primary efficacy measure was binge frequency. The primary analysis of efficacy was a repeated-measures random regression with treatment-by-time as the effect measure. RESULTS: Compared with placebo, topiramate was associated with a significantly greater rate of reduction in binge frequency, binge day frequency, body mass index, weight, and scores on the Clinical Global Impression severity scale and the Yale-Brown Obsessive Compulsive Scale (modified for binge eating). Topiramate was also associated with significantly greater reductions in binge frequency ( topiramate: 94%, placebo: 46%) and binge day frequency ( topiramate: 93%, placebo: 46%) and with a significantly higher level of response than placebo. The mean weight loss for topiramate-treated subjects who completed the study was 5.9 kg. Median topiramate dose was 212 mg/day (range=50-600). Nine patients (three receiving placebo, six given topiramate) discontinued because of adverse events. The most common reasons for discontinuing topiramate were headache (N=3) and paresthesias (N=2). CONCLUSIONS:
|
Authors | Susan L McElroy, Lesley M Arnold, Nathan A Shapira, Paul E Keck Jr, Norman R Rosenthal, M Rezaul Karim, Marc Kamin, James I Hudson |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 160
Issue 2
Pg. 255-61
(Feb 2003)
ISSN: 0002-953X [Print] United States |
PMID | 12562571
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticonvulsants
- Placebos
- Topiramate
- Fructose
|
Topics |
- Ambulatory Care
- Anticonvulsants
(administration & dosage, therapeutic use)
- Bulimia
(drug therapy, epidemiology)
- Comorbidity
- Double-Blind Method
- Drug Administration Schedule
- Fructose
(administration & dosage, analogs & derivatives, therapeutic use)
- Humans
- Obesity
(complications, epidemiology)
- Placebos
- Topiramate
- Treatment Outcome
|